BOUGHT: 3,324 shares @ $98.87
Total: $329K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 3,324 shares @ $98.87
Total: $329K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 2,176 shares @ $99.60
Total: $217K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 2,176 shares @ $99.60
Total: $217K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 3,000 shares @ $101.70
Total: $305K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 3,000 shares @ $101.70
Total: $305K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 1,500 shares @ $98.88
Total: $148K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 1,500 shares @ $98.88
Total: $148K
Filed Sep 24, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
Lappe Mark (Chief Executive Officer) bought 10,000 shares at an average price of $99.8784 per common share. (Date: 2026-09-28)
Lappe Mark (Chief Executive Officer) bought 10,000 shares at an average price of $99.8784 per common share. (Date: 2026-09-28)
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
• Chief Executive Officer bought $305K of INBX
• NCT is today's biggest tracked mover, −43.6%
marketclerk.com/today/2026-09-29
• Chief Executive Officer bought $305K of INBX
• NCT is today's biggest tracked mover, −43.6%
marketclerk.com/today/2026-09-29
If your fundraising is still ON, I am happy to add my chips to that. Would you please inbx me details to avoid another scam? 🙃
If your fundraising is still ON, I am happy to add my chips to that. Would you please inbx me details to avoid another scam? 🙃
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
BOUGHT: 5,000 shares @ $100.00
Total: $500K
Filed Sep 22, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
BOUGHT: 5,000 shares @ $100.00
Total: $500K
Filed Sep 22, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/INBX
#InsiderTrading #INBX #StockMarket
Biotech valuations can move sharply around clinical data, regulatory decisions, partnerships, and potential acquisitions. INBX has meaningful upside potential, but its limited revenue base makes clinical execution particularly important.
Biotech valuations can move sharply around clinical data, regulatory decisions, partnerships, and potential acquisitions. INBX has meaningful upside potential, but its limited revenue base makes clinical execution particularly important.
m.youtube.com/watch?v=InBX...
m.youtube.com/watch?v=InBX...
How can we ask elderly people — or *anyone* — to exercise discretion AND pay bills that look like this??!!
inbx dot biz, ayfkm
How can we ask elderly people — or *anyone* — to exercise discretion AND pay bills that look like this??!!
inbx dot biz, ayfkm
INBX is a high-risk, high-reward biotech bet. Insider buying and positive analyst sentiment are encouraging, but the stock's large run and elevated short interest show that expectations are already high.
INBX is a high-risk, high-reward biotech bet. Insider buying and positive analyst sentiment are encouraging, but the stock's large run and elevated short interest show that expectations are already high.
Kayyem Jon Faiz (Insider) bought 5,000 shares at an average price of $100.0000 per common share. (Date: 2026-09-23)
Kayyem Jon Faiz (Insider) bought 5,000 shares at an average price of $100.0000 per common share. (Date: 2026-09-23)